Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Gabriel Dan Duda, Ph.D., D.M.D.

Title
Institution
Department
Address
Phone
Fax
Profile Picture

Biography
University of Medicine Iasi, Romania, Iasi, RomaniaDMD09/1993Dentistry
Tohoku University Medical School, Sendai, JapanPhD03/2001GI Surgery
Harvard Medical School, Boston, MAPostdoctoral Fellow05/2004Tumor biology
1997 - 2001
Monbusho Graduate Research Fellowship
1998
Young Investigator Award, IAP
2001
Scholar-in-Training Award, AACR
2001
Travel Grant Award, Japanese Surgical Society
2002 - 2005
Postdoctoral Fellowship, Cancer Research Institute
2004
Travel Grant Award
2005 - 2007
Career Development Award for Cancer Research in Angiogenesis, AACR
2006
Scholarship, European Commission Marie Curie Actions Programme
2008 - 2009
Ira J. Spiro Translational Research Award
2009
Early Career Oncologists / Scientists (ECOS) Award EORTC-NCI-ASCO
2010 - 2011
Ira J. Spiro Translational Research Award
2011 - 2012
Ira J. Spiro Translational Research Award
2014
Capussotti Award, IASGO
2014
Keio University Lecture
2014 - 2016
Fellow, Andrew L. Warshaw, M.D., Institute for Pancreatic Cancer
2015
Keynote Speaker, Wolfsberg/ ESTRO Radiation Biology Meeting
2015
Tohoku Medical Society Lecture
2015
Keynote Lecture, Neuroononcology Group (NOA) Winterschool Freiburg, Germany
2015
Honoree of the One Hundred
2016
Heroes of Hope Award, Granara-Skerry Trust
2016
State-of-the-art Lecture, IASGO World Congress, Korea
2017
Plenary Lecture, Hong Kong International Oncology Forum
2017 - 2019
Partners HealthCare Innovator Awards
2017
Keio Medical Society Lecture
2018
IASGO Achievement Award
2018
Excellence Award on the occasion of the 100th Anniversary of Unification of the Romanian State
2020
Induction into the AIMBE College of Fellows – Class of 2020
2020
2020 Excellence Award – World Ambassador of Romanian Medicine
2021
Doctor Honoris Causa University of Medicine Iasi, Romania
2022
2021 AAAS Fellow
2022
Erudite Scholar-in-Residence

Overview
Education and Academic Appointments

Dr. Duda obtained a DMD from the University of Medicine Iasi, Romania, in 1993, and then earned a Ph.D. in Medical Sciences (Gastrointestinal Surgery) from Tohoku University Graduate School of Medicine, Sendai, Japan, in 2001. After graduation, he pursued postdoctoral training with Professor Rakesh K. Jain in the Steele Laboratories for Tumor Biology, Department of Radiation Oncology, MGH, and Harvard Medical School in Boston. Dr. Duda became a Junior Faculty member at Harvard (Instructor) in 2004. He then rose to Full Investigator at MGH Research Institute in 2016 and Associate Professor of Tumor Biology (Radiation Oncology) in 2012. In 2016, Dr. Duda was appointed Director of Translational Research in Gastrointestinal Radiation Oncology at MGH. In 2021, he received the honorary degree "Doctor Honoris Causa" from the University of Medicine Iasi, Romania, his Alma Mater.

Research Goals of the Duda Lab

Over the last decade and a half, Dr. Duda has built a productive Liver Cancer Research Program at Steele Laboratories for Tumor Biology. The translational goal of this program is to increase the durability of response to the most effective available therapies. The approach is to identify new cellular and molecular mechanisms of local and metastatic tumor progression and treatment resistance and validate them as new targets for combination therapies for these cancers.

His group studies the activity of agents targeting the tumor microenvironment (antiangiogenic or antifibrotic agents) or targeting the cancer cells (radiotherapy, chemotherapy, targeted agents) in combination with immunotherapy approaches. To this end, they developed preclinical models that reproduce hallmarks of human cancers (i.e., genetically engineered models of primary hepatocellular carcinoma and cholangiocarcinoma, and metastatic pancreatic, breast, and prostate carcinomas). In parallel, they are conducting correlative studies of biomarkers of response to the same approaches in clinical trials in cancer patients. Dr. Duda's research is supported by multiple R01 grants from the National Cancer Institute (NCI), Department of Defense (DoD) awards, and agreements with Industry partners.

Track Record and Service

Dr. Duda has authored over 250 publications so far. Of these, 160+ are original reports, including basic research published in Nature, Nature Medicine, Nature Biotechnology, Nature Genetics, Nature Communications, Cell, Cancer Cell, Science Translational Medicine, JNCI, Gut, and Hepatology, and clinical reports published in Journal of Clinical Oncology, npj Precision Oncology, and JAMA Oncology. Over the last two decades, he has been invited to present our results at over 200 local, national and international meetings, including in Grand Rounds (Harvard, Mayo Clinic, Yale, Fred Hutchinson Cancer Center), Plenary and State-of-the-art Talks (AACR, ISSCR, IASGO, IAP), and several Keynote Lectures. Dr. Duda has received multiple awards for his research, including from the AACR, Cancer Research Institute (CRI), IASGO, and MGH. He became an Honorary Member of the Academy of Medical Sciences of Romania in 2012; was inducted into the College of Fellows of the American Institute for Medical and Biomedical Engineering (AIMBE) in 2020; and was elected as a 2021 American Association for the Advancement of Science (AAAS) Fellow in 2022.

Dr. Duda has been a chartered or ad-hoc Member and Chair or co-Chair of US NCI, American Cancer Society (ACS), US Department of Defense (DOD), and Belgium FWO Med4 panels since 2012. He is a Founding Editor of Surgery, Gastroenterology and Oncology, a Senior Associate Editor of the International Journal of Radiation Oncology*Biology*Physics, and an Editorial Board member for several other journals, including Clinical & Translational Radiation Oncology, Journal of Hepatocellular Carcinoma, Digestive Surgery, and Cancers. Since 2015, he has been serving as the Secretary-General of the IASGO. In addition, Dr. Duda is a member of the American Association for the Study of Liver Diseases (AASLD) Liver Fibrosis Special Interest Group; a member of the NCI Hepatobiliary Task Force for Immuno-Oncology Biomarkers; and a member of the SWOG Cancer Research Network, GI and Translational Medicine GI Committees. Dr. Duda will chair the Forbeck Forum on “The Biology and Treatment of Hepatocellular Carcinoma” in 2023 and the "Boston Angiogenesis Meeting" in 2024.

Teaching

Dr. Duda teaches tumor biology and translational oncology through the daily supervision of postdoctoral research fellows and graduate and undergraduate students (50+ in the last 15 years). As a passionate supporter of IASGO's mission to globalize the best medical practice and knowledge worldwide, he has been coordinating, teaching, and directing Postgraduate Courses in 29 countries in Asia, Europe, Africa, and the Americas since 2013. He has taught nationally in ASTRO and RTOG translational meetings for residents and clinicians and locally in the MIT-HMS HST Program since 2005. In addition, he has been coordinating a research exchange student program with the University of Muenster, Germany, since 2015 and directing the Annual Course titled "Methods in Biomedical Engineering, Tumor Biology and Immunology" at MGH, since 2004. He authored the "IASGO Textbook of Multi-Disciplinary Management of Hepato-Pancreato-Biliary Diseases", published in 2022.

Research
The research activities and funding listed below are automatically derived from NIH ExPORTER and other sources, which might result in incorrect or missing items. Faculty can login to make corrections and additions.
  1. P01CA261669 (HONG, THEODORE S) Sep 21, 2021 - Aug 31, 2026
    NIH
    Integrating patient-specific clinical and biological factors towards individualizing utilization of proton and photon radiation therapy.
    Role: Core B Director
  2. W81XWH-21-1-0738 (DUDA, DAN G) Aug 1, 2021 - Jul 31, 2024
    DoD PRCRP
    Mechanisms Mediating the Immune Responses after Proton versus Photon Radiotherapy in IDH Mutant Liver Cancer
    Role Description: The aim of this grant is to use liver cancer models to validate the increased biological effects of proton therapy in vivo and link the increased efficacy with to a clinically testable tumor genotype and facilitate the design of combinations with immunotherapy.
    Role: Principal Investigator
  3. R03CA256764 (FERRONE, SOLDANO) Jul 8, 2021 - Jun 30, 2023
    NIH
    Radiation and CSPG4-specifc CAR T cell based combinatorial therapy for the in vivo treatment of TNBC
    Role: Multiple Principal Investigator
  4. R01CA247441 (MUNN, LANCE L) Jul 1, 2021 - Jun 30, 2026
    NIH
    Vascularized tumor explants for drug testing
    Role: Multiple Principal Investigator
  5. R01CA260857 (KUMAR, ANAND T.N.) Apr 1, 2021 - Mar 31, 2026
    NIH
    Multiplexed time domain fluorescence tomography of tumor biomarkers during immunotherapy
    Role: Multiple Principal Investigator

Bibliographic
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Chen S, Huang C, Liao G, Sun H, Xie Y, Liao C, Wang J, He M, Hu H, Dai Z, Ren X, Zeng X, Lin Z, Zhang GP, Xie W, Shen S, Li S, Peng S, Kuang DM, Zhao Q, Duda DG, Kuang M. Distinct single-cell immune ecosystems distinguish true and de novo HBV-related hepatocellular carcinoma recurrences. Gut. 2023 Jan 03. PMID: 36596711.
    Citations:    Fields:    
  2. Mohamed YI, Duda DG, Awiwi MO, Lee SS, Altameemi L, Xiao L, Morris JS, Wolff RA, Elsayes KM, Hatia RI, Qayyum A, Chamseddine SM, Rashid A, Yao JC, Mahvash A, Hassan MM, Amin HM, Kaseb AO. Plasma growth hormone is a potential biomarker of response to atezolizumab and bevacizumab in advanced hepatocellular carcinoma patients. Oncotarget. 2022 12 06; 13:1314-1321. PMID: 36473155; PMCID: PMC9726202.
    Citations:    Fields:    Translation:Humans
  3. Sasaki T, Shigeta K, Kitahara S, Suzuki Y, Matsui S, Seishima R, Okabayashi K, Duda DG, Kitagawa Y. Inhibition of STAT3 Promotes Effector T Cell Infiltration But also Immunosuppression in the HCC Tumor Microenvironment. Anticancer Res. 2022 Nov; 42(11):5205-5215. PMID: 36288859.
    Citations:    Fields:    Translation:AnimalsCells
  4. Duda DG, Jain RK. Revisiting Antiangiogenic Multikinase Inhibitors in the Era of Immune Checkpoint Blockade: The Case of Sorafenib. Cancer Res. 2022 10 17; 82(20):3665-3667. PMID: 36245248.
    Citations:    Fields:    Translation:HumansCells
  5. Saulnier-Sholler G, Duda DG, Bergendahl G, Ebb D, Snuderl M, Laetsch TW, Michlitsch J, Hanson D, Isakoff MS, Bielamowicz K, Kraveka JM, Ferguson W, Carmeliet P, De Deene A, Gijsen L, Jain RK. A Phase I Trial of TB-403 in Relapsed Medulloblastoma, Neuroblastoma, Ewing Sarcoma, and Alveolar Rhabdomyosarcoma. Clin Cancer Res. 2022 09 15; 28(18):3950-3957. PMID: 35833850; PMCID: PMC9481695.
    Citations:    Fields:    
  6. Kikuchi H, Matsui A, Morita S, Amoozgar Z, Inoue K, Ruan Z, Staiculescu D, Wong JS, Huang P, Yau T, Jain RK, Duda DG. Increased CD8+ T-cell Infiltration and Efficacy for Multikinase Inhibitors After PD-1 Blockade in Hepatocellular Carcinoma. J Natl Cancer Inst. 2022 09 09; 114(9):1301-1305. PMID: 35288743; PMCID: PMC9468280.
    Citations: 1     Fields:    
  7. Nagalo BM, Zhou Y, Loeuillard EJ, Dumbauld C, Barro O, Elliott NM, Baker AT, Arora M, Bogenberger JM, Meurice N, Petit J, Uson PLS, Aslam F, Raupach E, Gabere M, Basnakian A, Simoes CC, Cannon MJ, Post SR, Buetow K, Chamcheu JC, Barrett MT, Duda DG, Jacobs B, Vile R, Barry MA, Roberts LR, Ilyas S, Borad MJ. Characterization of Morreton virus as an oncolytic virotherapy platform for liver cancers. Hepatology. 2022 Sep 02. PMID: 36052732.
    Citations:    Fields:    
  8. Muñoz NM, Dupuis C, Williams M, Dixon K, McWatters A, Zhang J, Pavuluri S, Rao A, Duda DG, Kaseb A, Sheth RA. Immune modulation by molecularly targeted photothermal ablation in a mouse model of advanced hepatocellular carcinoma and cirrhosis. Sci Rep. 2022 08 24; 12(1):14449. PMID: 36002545; PMCID: PMC9402568.
    Citations: 3     Fields:    Translation:HumansAnimalsCells
  9. Martin JD, Lanning RM, Chauhan VP, Martin MR, Mousa AS, Kamoun WS, Han HS, Lee H, Stylianopoulos T, Bawendi MG, Duda DG, Brown EB, Padera TP, Fukumura D, Jain RK. Multiphoton Phosphorescence Quenching Microscopy Reveals Kinetics of Tumor Oxygenation during Antiangiogenesis and Angiotensin Signaling Inhibition. Clin Cancer Res. 2022 07 15; 28(14):3076-3090. PMID: 35584239; PMCID: PMC9355624.
    Citations: 1     Fields:    Translation:Animals
  10. Morita S, Duda DG. Refining genetic and molecular classifications to facilitate breakthrough treatments in intrahepatic cholangiocarcinoma: are we there yet? Gut. 2022 Jun 30. PMID: 35772925.
    Citations:    Fields:    
  11. Dima SO, Dumitrascu T, Popescu I, Duda DG. Using Molecular Subtyping of Pancreatic Ductal Adenocarcinoma for Multimodal Treatment Selection in Resectable Disease. Chirurgia (Bucur). 2022 Jun; 117(4):407-414. PMID: 36049097.
    Citations:    Fields:    Translation:Humans
  12. Pu Z, Duda DG, Zhu Y, Pei S, Wang X, Huang Y, Yi P, Huang Z, Peng F, Hu X, Fan X. VCP interaction with HMGB1 promotes hepatocellular carcinoma progression by activating the PI3K/AKT/mTOR pathway. J Transl Med. 2022 05 13; 20(1):212. PMID: 35562734; PMCID: PMC9102726.
    Citations:    Fields:    Translation:HumansCells
  13. How J, Ren S, Lombardi-Story J, Bergeron M, Foster J, Amrein PC, Brunner AM, Fathi AT, Hock H, Khachatryan A, Kikuchi H, Ng MR, Moran J, Narayan R, Neuberg D, Ramos A, Som T, Vartanian M, Chen YB, Duda DG, Hobbs GS. A nonrandomized phase I and biomarker trial of regorafenib in advanced myeloid malignancies. EJHaem. 2022 May; 3(2):434-442. PMID: 35846042; PMCID: PMC9175677.
    Citations:    
  14. Xiao Y, Chen J, Zhou H, Zeng X, Ruan Z, Pu Z, Jiang X, Matsui A, Zhu L, Amoozgar Z, Chen DS, Han X, Duda DG, Shi J. Combining p53 mRNA nanotherapy with immune checkpoint blockade reprograms the immune microenvironment for effective cancer therapy. Nat Commun. 2022 02 09; 13(1):758. PMID: 35140208; PMCID: PMC8828745.
    Citations: 1     Fields:    Translation:HumansAnimalsCells
  15. Hauth F, Roberts HJ, Hong TS, Duda DG. Leveraging Blood-Based Diagnostics to Predict Tumor Biology and Extend the Application and Personalization of Radiotherapy in Liver Cancers. Int J Mol Sci. 2022 Feb 09; 23(4). PMID: 35216045; PMCID: PMC8879105.
    Citations:    Fields:    Translation:Humans
  16. Chamseddine I, Kim Y, De B, El Naqa I, Duda DG, Wolfgang J, Pursley J, Paganetti H, Wo J, Hong T, Koay EJ, Grassberger C. Predictive Modeling of Survival and Toxicity in Patients With Hepatocellular Carcinoma After Radiotherapy. JCO Clin Cancer Inform. 2022 02; 6:e2100169. PMID: 35192402; PMCID: PMC8863122.
    Citations:    Fields:    Translation:Humans
  17. Duda DG. Targeting Tumor Microenvironment in Liver Cancers: Rationale, Current Progress, and Future Perspective. Keio J Med. 2022; 71(3):71. PMID: 36155490.
    Citations:    Fields:    Translation:Humans
  18. Gkika E, Adebahr S, Brenner A, Schimek-Jasch T, Radicioni G, Exner JP, Rühle A, Spohn SKB, Popp I, Zamboglou C, Sprave T, Firat E, Niedermann G, Nicolay NH, Nestle U, Grosu AL, Duda DG. Changes in Blood Biomarkers of Angiogenesis and Immune Modulation after Radiation Therapy and Their Association with Outcomes in Thoracic Malignancies. Cancers (Basel). 2021 Nov 16; 13(22). PMID: 34830880; PMCID: PMC8616228.
    Citations:    
  19. Ho WW, Gomes-Santos IL, Aoki S, Datta M, Kawaguchi K, Talele NP, Roberge S, Ren J, Liu H, Chen IX, Andersson P, Chatterjee S, Kumar AS, Amoozgar Z, Zhang Q, Huang P, Ng MR, Chauhan VP, Xu L, Duda DG, Clark JW, Pittet MJ, Fukumura D, Jain RK. Dendritic cell paucity in mismatch repair-proficient colorectal cancer liver metastases limits immune checkpoint blockade efficacy. Proc Natl Acad Sci U S A. 2021 11 09; 118(45). PMID: 34725151.
    Citations: 1     Fields:    Translation:HumansAnimalsCells
  20. Ferraro GB, Ali A, Luengo A, Kodack DP, Deik A, Abbott KL, Bezwada D, Blanc L, Prideaux B, Jin X, Posada JM, Chen J, Chin CR, Amoozgar Z, Ferreira R, Chen IX, Naxerova K, Ng C, Westermark AM, Duquette M, Roberge S, Lindeman NI, Lyssiotis CA, Nielsen J, Housman DE, Duda DG, Brachtel E, Golub TR, Cantley LC, Asara JM, Davidson SM, Fukumura D, Dartois VA, Clish CB, Jain RK, Vander Heiden MG. Author Correction: Fatty acid synthesis is required for breast cancer brain metastasis. Nat Cancer. 2021 11; 2(11):1243. PMID: 35122065.
    Citations:    
  21. Klein S, Duda DG. Machine Learning for Future Subtyping of the Tumor Microenvironment of Gastro-Esophageal Adenocarcinomas. Cancers (Basel). 2021 Sep 30; 13(19). PMID: 34638408; PMCID: PMC8507866.
    Citations: 2     
  22. Barroso-Sousa R, Keenan TE, Li T, Tayob N, Trippa L, Pastorello RG, Richardson Iii ET, Dillon D, Amoozgar Z, Overmoyer B, Schnitt SJ, Winer EP, Mittendorf EA, Van Allen E, Duda DG, Tolaney SM. Nivolumab in combination with cabozantinib for metastatic triple-negative breast cancer: a phase II and biomarker study. NPJ Breast Cancer. 2021 Aug 25; 7(1):110. PMID: 34433812.
    Citations: 1     
  23. Hauth F, Ho AY, Ferrone S, Duda DG. Radiotherapy to Enhance Chimeric Antigen Receptor T-Cell Therapeutic Efficacy in Solid Tumors: A Narrative Review. JAMA Oncol. 2021 Jul 01; 7(7):1051-1059. PMID: 33885725; PMCID: PMC8668197.
    Citations: 5     Fields:    Translation:HumansCells
  24. Boucher Y, Kumar AS, Posada JM, Gjini E, Pfaff K, Lipschitz M, Lako A, Duda DG, Rodig SJ, Hodi FS, Jain RK. Bevacizumab improves tumor infiltration of mature dendritic cells and effector T-cells in triple-negative breast cancer patients. NPJ Precis Oncol. 2021 Jun 29; 5(1):62. PMID: 34188163.
    Citations: 5     
  25. Tolaney SM, Ziehr DR, Guo H, Ng MR, Barry WT, Higgins MJ, Isakoff SJ, Brock JE, Ivanova EV, Paweletz CP, Demeo MK, Ramaiya NH, Overmoyer BA, Jain RK, Winer EP, Duda DG. Phase II and Biomarker Study of Cabozantinib in Metastatic Triple-Negative Breast Cancer Patients. Oncologist. 2021 Aug; 26(8):e1483. PMID: 33978307.
    Citations:    Fields:    
  26. Mohamed YI, Lee S, Xiao L, Hassan MM, Qayyum A, Hiatia R, Pestana RC, Haque A, George B, Rashid A, Duda DG, Elghazaly H, Wolff RA, Morris JS, Yao J, Amin HM, Kaseb AO. Insulin-like growth factor 1/Child-Turcotte-Pugh composite score as a predictor of treatment outcomes in patients with advanced hepatocellular carcinoma treated with sorafenib. Oncotarget. 2021 Apr 13; 12(8):756-766. PMID: 33889299.
    Citations: 1     Fields:    
  27. Ferraro GB, Ali A, Luengo A, Kodack DP, Deik A, Abbott KL, Bezwada D, Blanc L, Prideaux B, Jin X, Posada JM, Chen J, Chin CR, Amoozgar Z, Ferreira R, Chen IX, Naxerova K, Ng C, Westermark AM, Duquette M, Roberge S, Lindeman NI, Lyssiotis CA, Nielsen J, Housman DE, Duda DG, Brachtel E, Golub TR, Cantley LC, Asara JM, Davidson SM, Fukumura D, Dartois VA, Clish CB, Jain RK, Vander Heiden MG. FATTY ACID SYNTHESIS IS REQUIRED FOR BREAST CANCER BRAIN METASTASIS. Nat Cancer. 2021 04; 2(4):414-428. PMID: 34179825; PMCID: PMC8223728.
    Citations: 26     Translation:Humans
  28. Pfister D, Núñez NG, Pinyol R, Govaere O, Pinter M, Szydlowska M, Gupta R, Qiu M, Deczkowska A, Weiner A, Müller F, Sinha A, Friebel E, Engleitner T, Lenggenhager D, Moncsek A, Heide D, Stirm K, Kosla J, Kotsiliti E, Leone V, Dudek M, Yousuf S, Inverso D, Singh I, Teijeiro A, Castet F, Montironi C, Haber PK, Tiniakos D, Bedossa P, Cockell S, Younes R, Vacca M, Marra F, Schattenberg JM, Allison M, Bugianesi E, Ratziu V, Pressiani T, D'Alessio A, Personeni N, Rimassa L, Daly AK, Scheiner B, Pomej K, Kirstein MM, Vogel A, Peck-Radosavljevic M, Hucke F, Finkelmeier F, Waidmann O, Trojan J, Schulze K, Wege H, Koch S, Weinmann A, Bueter M, Rössler F, Siebenhüner A, De Dosso S, Mallm JP, Umansky V, Jugold M, Luedde T, Schietinger A, Schirmacher P, Emu B, Augustin HG, Billeter A, Müller-Stich B, Kikuchi H, Duda DG, Kütting F, Waldschmidt DT, Ebert MP, Rahbari N, Mei HE, Schulz AR, Ringelhan M, Malek N, Spahn S, Bitzer M, Ruiz de Galarreta M, Lujambio A, Dufour JF, Marron TU, Kaseb A, Kudo M, Huang YH, Djouder N, Wolter K, Zender L, Marche PN, Decaens T, Pinato DJ, Rad R, Mertens JC, Weber A, Unger K, Meissner F, Roth S, Jilkova ZM, Claassen M, Anstee QM, Amit I, Knolle P, Becher B, Llovet JM, Heikenwalder M. NASH limits anti-tumour surveillance in immunotherapy-treated HCC. Nature. 2021 04; 592(7854):450-456. PMID: 33762733; PMCID: PMC8046670.
    Citations: 118     Fields:    Translation:HumansAnimalsCells
  29. Li W, Li S, Chen IX, Liu Y, Ramjiawan RR, Leung CH, Gerweck LE, Fukumura D, Loeffler JS, Jain RK, Duda DG, Huang P. Combining losartan with radiotherapy increases tumor control and inhibits lung metastases from a HER2/neu-positive orthotopic breast cancer model. Radiat Oncol. 2021 Mar 04; 16(1):48. PMID: 33663521.
    Citations: 5     Fields:    Translation:AnimalsCells
  30. Ajdari A, Xie Y, Richter C, Niyazi M, Duda DG, Hong TS, Bortfeld T. Toward Personalized Radiation Therapy of Liver Metastasis: Importance of Serial Blood Biomarkers. JCO Clin Cancer Inform. 2021 03; 5:315-325. PMID: 33764817; PMCID: PMC8462658.
    Citations: 2     Fields:    Translation:HumansCells
  31. Aoki S, Inoue K, Klein S, Halvorsen S, Chen J, Matsui A, Nikmaneshi MR, Kitahara S, Hato T, Chen X, Kawakubo K, Nia HT, Chen I, Schanne DH, Mamessier E, Shigeta K, Kikuchi H, Ramjiawan RR, Schmidt TC, Iwasaki M, Yau T, Hong TS, Quaas A, Plum PS, Dima S, Popescu I, Bardeesy N, Munn LL, Borad MJ, Sassi S, Jain RK, Zhu AX, Duda DG. Placental growth factor promotes tumour desmoplasia and treatment resistance in intrahepatic cholangiocarcinoma. Gut. 2022 01; 71(1):185-193. PMID: 33431577; PMCID: PMC8666816.
    Citations: 4     Fields:    Translation:HumansAnimalsCells
  32. Pinter M, Jain RK, Duda DG. The Current Landscape of Immune Checkpoint Blockade in Hepatocellular Carcinoma: A Review. JAMA Oncol. 2021 Jan 01; 7(1):113-123. PMID: 33090190; PMCID: PMC8265820.
    Citations: 51     Fields:    Translation:Humans
  33. Gerstner ER, Emblem KE, Yen YF, Dietrich J, Jordan JT, Catana C, Wenchin KL, Hooker JM, Duda DG, Rosen BR, Kalpathy-Cramer J, Jain RK, Batchelor TT. Vascular dysfunction promotes regional hypoxia after bevacizumab therapy in recurrent glioblastoma patients. Neurooncol Adv. 2020 Jan-Dec; 2(1):vdaa157. PMID: 33392506; PMCID: PMC7764510.
    Citations: 4     
  34. Nayak L, Molinaro AM, Peters K, Clarke JL, Jordan JT, de Groot J, Nghiemphu L, Kaley T, Colman H, McCluskey C, Gaffey S, Smith TR, Cote DJ, Severgnini M, Yearley JH, Zhao Q, Blumenschein WM, Duda DG, Muzikansky A, Jain RK, Wen PY, Reardon DA. Randomized Phase II and Biomarker Study of Pembrolizumab plus Bevacizumab versus Pembrolizumab Alone for Patients with Recurrent Glioblastoma. Clin Cancer Res. 2021 02 15; 27(4):1048-1057. PMID: 33199490; PMCID: PMC8284901.
    Citations: 33     Fields:    Translation:HumansCTClinical Trials
  35. Shigeta K, Matsui A, Kikuchi H, Klein S, Mamessier E, Chen IX, Aoki S, Kitahara S, Inoue K, Shigeta A, Hato T, Ramjiawan RR, Staiculescu D, Zopf D, Fiebig L, Hobbs GS, Quaas A, Dima S, Popescu I, Huang P, Munn LL, Cobbold M, Goyal L, Zhu AX, Jain RK, Duda DG. Regorafenib combined with PD1 blockade increases CD8 T-cell infiltration by inducing CXCL10 expression in hepatocellular carcinoma. J Immunother Cancer. 2020 11; 8(2). PMID: 33234602; PMCID: PMC7689089.
    Citations: 20     Fields:    Translation:HumansAnimalsCells
  36. Abdel-Wahab R, Hassan MM, George B, Carmagnani Pestana R, Xiao L, Lacin S, Yalcin S, Shalaby AS, Al-Shamsi HO, Raghav K, Wolff RA, Yao JC, Girard L, Haque A, Duda DG, Dima S, Popescu I, Elghazaly HA, Vauthey JN, Aloia TA, Tzeng CW, Chun YS, Rashid A, Morris JS, Amin HM, Kaseb AO. Impact of Integrating Insulin-Like Growth Factor 1 Levels into Model for End-Stage Liver Disease Score for Survival Prediction in Hepatocellular Carcinoma Patients. Oncology. 2020; 98(12):836-846. PMID: 33027788.
    Citations: 2     Fields:    Translation:Humans
  37. Goyal L, Sirard C, Schrag M, Kagey MH, Eads JR, Stein S, El-Khoueiry AB, Manji GA, Abrams TA, Khorana AA, Miksad R, Mahalingam D, Zhu AX, Duda DG. Phase I and Biomarker Study of the Wnt Pathway Modulator DKN-01 in Combination with Gemcitabine/Cisplatin in Advanced Biliary Tract Cancer. Clin Cancer Res. 2020 12 01; 26(23):6158-6167. PMID: 32878766.
    Citations: 13     Fields:    Translation:HumansCellsCTClinical Trials
  38. Martin JD, Duda DG, Jain RK. Going Beyond VEGF Pathway Inhibition for Antiangiogenic Cancer Therapy: Is Inhibition of the PP2A/B55a Complex the Answer? Circ Res. 2020 08 28; 127(6):724-726. PMID: 32853096.
    Citations:    Fields:    Translation:HumansCells
  39. Nagalo BM, Breton CA, Zhou Y, Arora M, Bogenberger JM, Barro O, Steele MB, Jenks NJ, Baker AT, Duda DG, Roberts LR, Russell SJ, Peng KW, Borad MJ. Oncolytic Virus with Attributes of Vesicular Stomatitis Virus and Measles Virus in Hepatobiliary and Pancreatic Cancers. Mol Ther Oncolytics. 2020 Sep 25; 18:546-555. PMID: 32839735.
    Citations: 5     
  40. Duda DG, Dima SO, Cucu D, Sorop A, Klein S, Ancukiewicz M, Kitahara S, Iacob S, Bacalbasa N, Tomescu D, Herlea V, Tanase C, Croitoru A, Popescu I. Potential Circulating Biomarkers of Recurrence after Hepatic Resection or Liver Transplantation in Hepatocellular Carcinoma Patients. Cancers (Basel). 2020 May 18; 12(5). PMID: 32443546; PMCID: PMC7281651.
    Citations: 3     
  41. Ho AY, Wright JL, Blitzblau RC, Mutter RW, Duda DG, Norton L, Bardia A, Spring L, Isakoff SJ, Chen JH, Grassberger C, Bellon JR, Beriwal S, Khan AJ, Speers C, Dunn SA, Thompson A, Santa-Maria CA, Krop IE, Mittendorf E, King TA, Gupta GP. Optimizing Radiation Therapy to Boost Systemic Immune Responses in Breast Cancer: A Critical Review for Breast Radiation Oncologists. Int J Radiat Oncol Biol Phys. 2020 09 01; 108(1):227-241. PMID: 32417409.
    Citations: 6     Fields:    Translation:Humans
  42. Kongpetch S, Jusakul A, Lim JQ, Ng CCY, Chan JY, Rajasegaran V, Lim TH, Lim KH, Choo SP, Dima S, Popescu I, Duda DG, Kukongviriyapan V, Khuntikeo N, Pairojkul C, Rozen SG, Tan P, Teh BT. Lack of Targetable FGFR2 Fusions in Endemic Fluke-Associated Cholangiocarcinoma. JCO Glob Oncol. 2020 04; 6:628-638. PMID: 32315234.
    Citations: 6     Fields:    Translation:HumansAnimals
  43. Millar DG, Ramjiawan RR, Kawaguchi K, Gupta N, Chen J, Zhang S, Nojiri T, Ho WW, Aoki S, Jung K, Chen I, Shi F, Heather JM, Shigeta K, Morton LT, Sepulveda S, Wan L, Joseph R, Minogue E, Khatri A, Bardia A, Ellisen LW, Corcoran RB, Hata AN, Pai SI, Jain RK, Fukumura D, Duda DG, Cobbold M. Antibody-mediated delivery of viral epitopes to tumors harnesses CMV-specific T cells for cancer therapy. Nat Biotechnol. 2020 04; 38(4):420-425. PMID: 32042168.
    Citations: 19     Fields:    Translation:HumansAnimalsCells
  44. Mpekris F, Voutouri C, Baish JW, Duda DG, Munn LL, Stylianopoulos T, Jain RK. Combining microenvironment normalization strategies to improve cancer immunotherapy. Proc Natl Acad Sci U S A. 2020 02 18; 117(7):3728-3737. PMID: 32015113.
    Citations: 58     Fields:    Translation:HumansCells
  45. Chen J, Duda DG. Overcoming sorafenib treatment-resistance in hepatocellular carcinoma: A future perspective at a time of rapidly changing treatment paradigms. EBioMedicine. 2020 02; 52:102644. PMID: 32014823.
    Citations: 4     Fields:    Translation:Humans
  46. Kong N, Tao W, Ling X, Wang J, Xiao Y, Shi S, Ji X, Shajii A, Gan ST, Kim NY, Duda DG, Xie T, Farokhzad OC, Shi J. Synthetic mRNA nanoparticle-mediated restoration of p53 tumor suppressor sensitizes p53-deficient cancers to mTOR inhibition. Sci Transl Med. 2019 12 18; 11(523). PMID: 31852795; PMCID: PMC7024563.
    Citations: 46     Fields:    Translation:HumansAnimalsCells
  47. Plotkin SR, Duda DG, Muzikansky A, Allen J, Blakeley J, Rosser T, Campian JL, Clapp DW, Fisher MJ, Tonsgard J, Ullrich N, Thomas C, Cutter G, Korf B, Packer R, Karajannis MA. Multicenter, Prospective, Phase II and Biomarker Study of High-Dose Bevacizumab as Induction Therapy in Patients With Neurofibromatosis Type 2 and Progressive Vestibular Schwannoma. J Clin Oncol. 2019 12 10; 37(35):3446-3454. PMID: 31626572; PMCID: PMC7098833.
    Citations: 20     Fields:    Translation:HumansCTClinical Trials
  48. Shigeta K, Datta M, Hato T, Kitahara S, Chen IX, Matsui A, Kikuchi H, Mamessier E, Aoki S, Ramjiawan RR, Ochiai H, Bardeesy N, Huang P, Cobbold M, Zhu AX, Jain RK, Duda DG. Dual Programmed Death Receptor-1 and Vascular Endothelial Growth Factor Receptor-2 Blockade Promotes Vascular Normalization and Enhances Antitumor Immune Responses in Hepatocellular Carcinoma. Hepatology. 2020 04; 71(4):1247-1261. PMID: 31378984.
    Citations: 92     Fields:    Translation:AnimalsCells
  49. Gerstner ER, Emblem KE, Chang K, Vakulenko-Lagun B, Yen YF, Beers AL, Dietrich J, Plotkin SR, Catana C, Hooker JM, Duda DG, Rosen B, Kalpathy-Cramer J, Jain RK, Batchelor T. Bevacizumab Reduces Permeability and Concurrent Temozolomide Delivery in a Subset of Patients with Recurrent Glioblastoma. Clin Cancer Res. 2020 01 01; 26(1):206-212. PMID: 31558474.
    Citations: 18     Fields:    Translation:Humans
  50. Leone JP, Duda DG, Hu J, Barry WT, Trippa L, Gerstner ER, Jain RK, Tan S, Lawler E, Winer EP, Lin NU, Tolaney SM. A phase II study of cabozantinib alone or in combination with trastuzumab in breast cancer patients with brain metastases. Breast Cancer Res Treat. 2020 Jan; 179(1):113-123. PMID: 31541381.
    Citations: 9     Fields:    Translation:HumansCTClinical Trials
  51. Lee EQ, Muzikansky A, Duda DG, Gaffey S, Dietrich J, Nayak L, Chukwueke UN, Beroukhim R, Doherty L, Laub CK, LaFrankie D, Fontana B, Stefanik J, Ruland S, Caruso V, Bruno J, Ligon K, Reardon DA, Wen PY. Phase II trial of ponatinib in patients with bevacizumab-refractory glioblastoma. Cancer Med. 2019 10; 8(13):5988-5994. PMID: 31444999.
    Citations: 11     Fields:    Translation:HumansCTClinical Trials
  52. Sãftoiu A, Bhutani MS, Itoi T, Arcidiacono PG, Bories E, Cazacu IM, Constantin A, Coronel E, Dietrich CF, Duda DG, Garcia JI, Hocke M, Ignee A, Jenssen C, Jinga M, Khor C, Oppong KW, Pereira S, Petrone MC, Santo E, Seicean A, Seo DW, Siyu S, Vilmann P, Waxman I, Yeaton P. Changes in tumor vascularity depicted by contrast-enhanced EUS as a predictor of prognosis and treatment efficacy in patients with unresectable pancreatic cancer (PEACE): A study protocol. Endosc Ultrasound. 2019 Jul-Aug; 8(4):235-240. PMID: 31249159.
    Citations: 6     
  53. Murphy JE, Wo JY, Ryan DP, Clark JW, Jiang W, Yeap BY, Drapek LC, Ly L, Baglini CV, Blaszkowsky LS, Ferrone CR, Parikh AR, Weekes CD, Nipp RD, Kwak EL, Allen JN, Corcoran RB, Ting DT, Faris JE, Zhu AX, Goyal L, Berger DL, Qadan M, Lillemoe KD, Talele N, Jain RK, DeLaney TF, Duda DG, Boucher Y, Fernández-Del Castillo C, Hong TS. Total Neoadjuvant Therapy With FOLFIRINOX in Combination With Losartan Followed by Chemoradiotherapy for Locally Advanced Pancreatic Cancer: A Phase 2 Clinical Trial. JAMA Oncol. 2019 Jul 01; 5(7):1020-1027. PMID: 31145418; PMCID: PMC6547247.
    Citations: 138     Fields:    Translation:HumansCTClinical Trials
  54. Ly KI, Vakulenko-Lagun B, Emblem KE, Ou Y, Da X, Betensky RA, Kalpathy-Cramer J, Duda DG, Jain RK, Chi AS, Plotkin SR, Batchelor TT, Sorensen G, Rosen BR, Gerstner ER. Publisher Correction: Probing tumor microenvironment in patients with newly diagnosed glioblastoma during chemoradiation and adjuvant temozolomide with functional MRI. Sci Rep. 2019 Jun 14; 9(1):8721. PMID: 31197238.
    Citations:    Fields:    
  55. Amoozgar Z, Jain RK, Duda DG. Role of Apelin in Glioblastoma Vascularization and Invasion after Anti-VEGF Therapy: What Is the Impact on the Immune System? Cancer Res. 2019 05 01; 79(9):2104-2106. PMID: 31043429; PMCID: PMC6601607.
    Citations: 4     Fields:    Translation:Humans
  56. Richter C, Andronesi OC, Borra RJH, Voigt F, Löck S, Duda DG, Guimaraes AR, Hong TS, Bortfeld TR, Seco J. Inter-patient variations of radiation-induced normal-tissue changes in Gd-EOB-DTPA-enhanced hepatic MRI scans during fractionated proton therapy. Clin Transl Radiat Oncol. 2019 Sep; 18:113-119. PMID: 31341986; PMCID: PMC6630151.
    Citations: 1     
  57. Cleary JM, Horick NK, McCleary NJ, Abrams TA, Yurgelun MB, Azzoli CG, Rubinson DA, Brooks GA, Chan JA, Blaszkowsky LS, Clark JW, Goyal L, Meyerhardt JA, Ng K, Schrag D, Savarese DMF, Graham C, Fitzpatrick B, Gibb KA, Boucher Y, Duda DG, Jain RK, Fuchs CS, Enzinger PC. FOLFOX plus ziv-aflibercept or placebo in first-line metastatic esophagogastric adenocarcinoma: A double-blind, randomized, multicenter phase 2 trial. Cancer. 2019 07 01; 125(13):2213-2221. PMID: 30913304; PMCID: PMC6763367.
    Citations: 7     Fields:    Translation:HumansCTClinical Trials
  58. Askoxylakis V, Ferraro GB, Badeaux M, Kodack DP, Kirst I, Shankaraiah RC, Wong CSF, Duda DG, Fukumura D, Jain RK. Dual endothelin receptor inhibition enhances T-DM1 efficacy in brain metastases from HER2-positive breast cancer. NPJ Breast Cancer. 2019; 5:4. PMID: 30675514; PMCID: PMC6333771.
    Citations: 7     
  59. Ly KI, Vakulenko-Lagun B, Emblem KE, Ou Y, Da X, Betensky RA, Kalpathy-Cramer J, Duda DG, Jain RK, Chi AS, Plotkin SR, Batchelor TT, Sorensen G, Rosen BR, Gerstner ER. Probing tumor microenvironment in patients with newly diagnosed glioblastoma during chemoradiation and adjuvant temozolomide with functional MRI. Sci Rep. 2018 11 20; 8(1):17062. PMID: 30459364.
    Citations: 8     Fields:    Translation:Humans
  60. Hong TS, Grassberger C, Yeap BY, Jiang W, Wo JY, Goyal L, Clark JW, Crane CH, Koay EJ, Dima S, Eyler CE, Popescu I, DeLaney TF, Zhu AX, Duda DG. Pretreatment plasma HGF as potential biomarker for susceptibility to radiation-induced liver dysfunction after radiotherapy. NPJ Precis Oncol. 2018; 2:22. PMID: 30374460; PMCID: PMC6194077.
    Citations: 10     
  61. Goyal L, Zheng H, Abrams TA, Miksad R, Bullock AJ, Allen JN, Yurgelun MB, Clark JW, Kambadakone A, Muzikansky A, Knowles M, Galway A, Afflitto AJ, Dinicola CF, Regan E, Hato T, Mamessier E, Shigeta K, Jain RK, Duda DG, Zhu AX. A Phase II and Biomarker Study of Sorafenib Combined with Modified FOLFOX in Patients with Advanced Hepatocellular Carcinoma. Clin Cancer Res. 2019 01 01; 25(1):80-89. PMID: 30190369; PMCID: PMC6320284.
    Citations: 23     Fields:    Translation:HumansCellsCTClinical Trials
  62. Lee EQ, Duda DG, Muzikansky A, Gerstner ER, Kuhn JG, Reardon DA, Nayak L, Norden AD, Doherty L, LaFrankie D, Stefanik J, Vardam T, Smith K